For Media

The media's connection to global experts in medicine, science, nursing and public health.

The Office of News & Communications connects print, broadcast and online media interested in learning more about research, education, and patient care to experts at Vanderbilt Health.

Interested in a phone, email or in-person interview? Call (615) 322-4747.
All media are required to be escorted by a member of our department when visiting facilities and patient care areas.

News Releases

Recent press releases approved for use by print, broadcast or online media.

(iStock)
August 26, 2026

Duchenne muscular dystrophy patients are focus of GLP-1 therapy for obesity study

The study will begin enrolling eligible patients in September. Thirty participants, ages 12 and older, will be randomized to receive either a placebo or the GLP-1 receptor agonist semaglutide.

By Jessica Pasley
Jordyn Bugarin, 22, was the only patient in the United States enrolled in the OPTIMA clinical trial for fibrodysplasia ossificans progressiva (FOP), a rare genetic condition that causes muscle and connective tissue to turn into bone. (photo by Erin O. Smith)
August 20, 2026

Her muscles are slowly turning to bone. She was the only American in a trial that might stop it.

As part of the clinical trial, Jordyn Bugarin regularly traveled to Vanderbilt Health, navigating a complex study while living with a disease that can flare unpredictably and permanently limit movement. The experimental drug received federal approval on Aug. 19.

By Craig Boerner
August 18, 2026

As schedules change, health care advocates encourage back seat second looks to prevent hot car deaths

It only takes 10 minutes for the temperature inside a vehicle to rise 19 degrees and continue to rise. Even on cooler days closer to 70 degrees, children can experience vehicular heatstroke.

By Jessica Pasley
August 18, 2026

Could GLP-1s help treat opioid use disorder? Vanderbilt Health study now enrolling

The study, Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder (TAB), is a double-blind, randomized, placebo-controlled trial conducted through the National Institute on Drug Abuse’s Clinical Trials Network.

By Jessica Pasley
August 18, 2026

Vanderbilt Health’s Annet Kirabo to receive major award for hypertension research 

The award will be presented Oct. 10 during the American Heart Association’s Hypertension Scientific Session in Arlington, Virginia.

By Bill Snyder
August 13, 2026

Yale’s Jasmiry Bennett named Vice President and Chief Advanced Practice Officer for Vanderbilt Health

As Vanderbilt Health’s first Vice President and Chief Advanced Practice Officer, Bennett will provide strategic leadership for the APP community across the enterprise and help shape the future of advanced practice.

By Craig Boerner